

GenSight Biologics Reports its Cash Position as of September 30, 2018

Paris, France, October 24, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2018.

Cash and cash equivalents

GenSight Biologics' cash and cash equivalents was €39.2 million as of September 30, 2018, compared to €41.7 million as of June 30, 2018.

Number of outstanding shares

As of September 30, 2018, GenSight Biologics' number of outstanding shares was 24,766,723 ordinary shares.

GenSight Biologics will report its cash position as of December 31, 2018 on January 23, 2019.

Contacts

GenSight Biologics

Thomas Gidoïn
Chief Financial Officer
tgidoïn@gensight-biologics.com
+33 (0)1 76 21 72 20

RooneyPartners

Media Relations
Marion Janic
mjanic@rooneyco.com
+1-212-223-4017

The Trout Group

US Investor Relations
Chad Rubin
crubin@troutgroup.com
+1-646-378-2947

James Palmer

Europe Investor Relations
j.palmer@orpheonfinance.com
+33 7 60 92 77 74

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.